B
Bull
Bull · 25%SPRC
$7.05
Scenario price
$2.000
-0.898 (-44.90%)At close
Loading chart…
- High
- 5.330
- Open
- 4.200
- VWAP
- 2.99
- Volume
- 34.77M
- Mkt Cap
- 2.77M
- Low
- 1.630
- Amount
- 103.84M
- EV/EBITDA, TTM
- 0.00
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
AI analysis of Scisparc Ltd (SPRC)
HoldCurrently, SciSparc Ltd (SPRC) is not a strong buy due to its recent performance and financial metrics. The stock is trading at $4.47, which is significantly down 64.52% year-to-date and 85.69% over the past year. The RSI is at 42.375, indicating it is nearing oversold territory, but it has not yet reached a buying signal. Additionally, the forward P/E ratio is at 0, reflecting uncertainty in future earnings. While there was a notable 70.54% increase in stock price recently due to advancements in its technology, the overall trend remains negative, and the stock has a high risk of further decline given its current financial instability and negative margins. The main risk is highlighted by the net margin of -2041.65% in Q2 2025, indicating severe losses.
Valuation Metrics
The current forward P/E ratio for Scisparc Ltd (SPRC) is 0.00, compared to its 5-year average forward P/E of -7.97.
Alphio AI Price Scenarios for SPRC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
4.510-15NewsfilterSciSparc Shifts Strategic Focus to Agentic AI Technologies
- 8.509-02Newsfilter
NeuroThera Pursues FDA Orphan Drug Designation for SCI-110
- 4.508-26Newsfilter
SciSparc Appoints AI Expert to Strengthen Strategic Focus
- 8.508-12Newsfilter
NeuroThera Secures Japanese Patent for Pain Treatment
9.008-05GlobenewswireSciSparc Initiates NeuroThera Phase IIb Clinical Trial
SPRC FAQ — answered by Alphio AI
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Currently, SciSparc Ltd (SPRC) is not a strong buy due to its recent performance and financial metrics. The stock is trading at $4.47, which is significantly down 64.52% year-to-date and 85.69% over the past year. The RSI is at 42.375, indicating it is nearing oversold territory, but it has not yet reached a buying signal. Additionally, the forward P/E ratio is at 0, reflecting uncertainty in future earnings. While there was a notable 70.54% increase in stock price recently due to advancements in its technology, the overall trend remains negative, and the stock has a high risk of further decline given its current financial instability and negative margins. The main risk is highlighted by the net margin of -2041.65% in Q2 2025, indicating severe losses.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.